Sildenafil for Antidepressant-Induced Anorgasmia in Women
Sildenafil can be effective for treating antidepressant-induced anorgasmia in women, particularly those on selective serotonin reuptake inhibitors (SSRIs), based on the highest quality randomized controlled trial evidence, though current guidelines do not formally recommend it due to mixed results in broader female sexual dysfunction populations.
Evidence-Based Recommendation
The most definitive evidence comes from a 2008 multicenter randomized controlled trial that specifically studied women with antidepressant-associated sexual dysfunction 1. This study demonstrated that sildenafil significantly improved sexual function in premenopausal women experiencing sexual dysfunction from SRIs, with a mean Clinical Global Impression score difference of 0.8 (P = .001) compared to placebo. Importantly, these women had remitted depression and were previously sexually functioning before starting antidepressants—making this the most relevant population for your question.
The Critical Distinction
Here's where clinical context matters: The NCCN guidelines explicitly state they do not recommend PDE5 inhibitors for female sexual dysfunction 2, but this recommendation is based on studies of women with primary sexual arousal disorder, not antidepressant-induced dysfunction. The guideline notes that PDE5 inhibitors "showed contradictory results in randomized clinical trials of various noncancer populations of women being treated for sexual arousal disorder" 2.
This is a different population than women with medication-induced anorgasmia. The distinction is crucial because:
- Women with antidepressant-induced sexual dysfunction had normal function before medication
- The mechanism involves serotonergic effects on sexual response, not primary vascular or arousal pathology
- The 2008 RCT specifically targeted this population and showed benefit 1
Practical Implementation
Dosing approach:
- Start with sildenafil 50 mg taken approximately 1 hour before sexual activity 1, 3
- Can increase to 100 mg if partial or no response 1, 3
- The FDA labeling confirms sildenafil is not indicated for women, but this reflects lack of formal approval rather than safety concerns 4
Expected outcomes:
- Most women in the open-label study reported "significant reversal of sexual dysfunction, usually with the first dose" 3
- The RCT showed sustained benefit over 8 weeks 1
- Depression scores remained stable, indicating no interference with antidepressant efficacy 1
Important Caveats
Common side effects include headache, flushing, and dyspepsia, but no serious adverse events led to withdrawal in the trials 1.
Contraindications from FDA labeling that apply to women:
- Concurrent nitrate use (absolute contraindication) 4
- Recent cardiovascular events (within 6 months) 4
- Severe hypotension or uncontrolled hypertension 4
- Concurrent use of strong CYP3A4 inhibitors requires dose adjustment 4
The failure in broader FSAD populations 5 suggests sildenafil works specifically when sexual dysfunction is medication-induced rather than primary, supporting a targeted approach for antidepressant-related anorgasmia.
Alternative Considerations
Before prescribing sildenafil, ensure:
- Depression is adequately treated and in remission 1
- Hormone levels are normal (though the RCT showed benefit regardless) 1
- The sexual dysfunction temporally correlates with antidepressant initiation
- Other causes of sexual dysfunction are excluded
If sildenafil is ineffective or not tolerated, the literature supports considering yohimbine, buspirone as adjuncts, or temporary drug holidays 6, though these have less robust evidence than sildenafil for this specific indication.